Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Researchers screened cancer cell lines to detect mutations and drug combinations that might sensitize tumors to drugs that impair anti-apoptosis proteins.
A proteomic analysis of pancreatic ductal adenocarcinoma tumor and stromal samples led to a stromal protein that appears to coincide with tumor aggressiveness.
Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
Researchers used genomic approaches to search for disease clues in purified cells from ileum or colon biopsies of pediatric inflammatory bowel disease patients.
Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
